8 recruiting, 4 active not recruiting, 2 not yet recruiting, 2 terminated. 11 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Advanced Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Advanced Clear Cell Renal Cell Carcinoma trials Research Report on Advanced Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Casdatifan, Cabozantinib, Placebo - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Arcus Biosciences, Inc. | 720 | 2025-09-08 | 2026-11-02 |
| 177LuPSMA in Renal Cell Carcinoma 177Lu-PSMA-617 - Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 24 | 2025-07-31 | 2026-02-24 |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC Volrustomig, Casdatifan - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Active not recruiting | AstraZeneca | 9 | 2025-07-28 | 2026-08-03 |
| Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma HS-10516 + Lenvatinib - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 104 | 2025-07-10 | 2025-08-01 |
| A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC CGC738 - Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Not yet recruiting | RenJi Hospital | 28 | 2025-05-25 | 2025-04-24 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Avelumab, Palbociclib and Axitinib in Advanced RCC Axitinib, Palbociclib, Avelumab - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Withdrawn | Bradley A. McGregor, MD | 2024-05-31 | 2023-09-07 | |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Cabozantinib, Ipilimumab, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 54 | 2022-12-06 | 2026-08-19 |
| A Clinical Study of 6MW3211 in Patients With Renal Cancer 6MW3211 - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 30 | 2022-09-01 | 2022-08-17 |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Nivolumab, Quality-of-Life Assessment, Questionnaire Administration - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2022-05-03 | 2026-03-20 |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Cabozantinib, Everolimus, Lenvatinib - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2022-02-16 | 2026-09-14 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2021-11-01 | 2026-03-05 |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Aldesleukin, Pembrolizumab - Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer | Phase 1 | Terminated | University of Washington | 6 | 2018-08-28 | 2025-12-08 |
Carcinoma, Renal Cell (14) · Clear-cell metastatic renal cell carcinoma (12) · Kidney Neoplasms (4) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Tertiary Lymphoid Structures (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Kidney Diseases (15) · Male Urogenital Diseases (15) · Neoplasms (15) · Neoplasms by Site (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15) · Urologic Diseases (15) · Urologic Neoplasms (15) · Adenocarcinoma (14) · Carcinoma (14) · Neoplasms by Histologic Type (14) · Neoplasms, Glandular and Epithelial (14) · Kidney Neoplasms (11)
Nivolumab (7) · CTLA-4 Antigen (5) · Ipilimumab (5) · Specimen Handling (5) · cabozantinib (5) · Axitinib (4) · Magnetic Resonance Spectroscopy (3) · lenvatinib (3) · Biopsy (2) · palbociclib (2) · pembrolizumab (2) · Everolimus (1) · Hyaluronoglucosaminidase (1) · Immunoglobulin G (1) · Pluvicto (1)
City of Hope Medical Center (3) · M.D. Anderson Cancer Center (2) · Arcus Biosciences, Inc. (1) · AstraZeneca (1) · Bradley A. McGregor, MD (1) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · Mayo Clinic (1) · Osel, Inc. (1) · RenJi Hospital (1) · SWOG Cancer Research Network (1) · Stephanie Berg (1) · University of Washington (1)
United States (13) · Australia (2) · South Korea (2) · Argentina (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Romania (1)
Sumanta K Pal (2) · Alex Chehrazi-Raffle, MD (1) · Andrew W Hahn, MD (1) · Bradley McGregor, MD (1) · Brian A. Costello, MD (1) · Brian I Rini, MD (1) · Charles B Nguyen (1) · Pavlos Msaouel (1) · Pedro Barata (1) · Praful Ravi, MB BCHir, MRCP (1) · Scott S. Tykodi (1) · Stephanie Berg, DO (1)
PMID 38942995, PMID 40212021, PMID 41545068, PMID 42246926
P30CA033572 (4), P30CA068485 (1), U10CA180888 (1)